Source comparison
Tesamorelin + Ipamorelin: Injection vs Oral — Comparison
Subcutaneous Injection >80% intact peptide absorption Direct capillary uptake → systemic circulation → pituitary GHS-R1a binding 30–60 minutes post-injection Peptide structure preserved; no enzymatic degradation FDA Phase III trials; peer-reviewed publications
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- >80% intact peptide absorption
- Direct capillary uptake → systemic circulation → pituitary GHS-R1a binding
- 30–60 minutes post-injection
- Peptide structure preserved; no enzymatic degradation
- FDA Phase III trials; peer-reviewed publications in Endocrine Reviews and JCEM
- Oral Administration (Unmodified)
- <2% (mostly degraded fragments)
- Proteolytic cleavage by pepsin, trypsin, chymotrypsin in GI tract
- None. Insufficient intact peptide reaches circulation
- Complete peptide bond cleavage; amino acids absorbed as dietary protein
- Zero validated clinical trials for oral Tesamorelin or Ipamorelin
- Oral (Modified Analogs)
- 10–30% (compound-dependent)
- Chemical modification (PEGylation, cyclisation) protects against enzymes
- Variable; slower onset than injection
- Structural modification alters receptor affinity and half-life
- Limited trials on specific modified peptides (not Tesamorelin/Ipamorelin)
- The table clarifies what manufacturers often obscure: unmodified Tesamorelin and Ipamorelin do not survive oral administration. Modified analogs that do survive are chemically distinct compounds with different safety and efficacy profiles.